Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) Short Interest Up 1,500.0% in December

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) saw a significant growth in short interest during the month of December. As of December 31st, there was short interest totalling 36,800 shares, a growth of 1,500.0% from the December 15th total of 2,300 shares. Based on an average trading volume of 214,500 shares, the short-interest ratio is presently 0.2 days.

Chugai Pharmaceutical Trading Down 0.6 %

Shares of Chugai Pharmaceutical stock traded down $0.13 during trading on Monday, reaching $21.10. The company’s stock had a trading volume of 152,155 shares, compared to its average volume of 354,793. The stock has a market capitalization of $69.44 billion, a P/E ratio of 27.05 and a beta of 0.81. Chugai Pharmaceutical has a one year low of $14.52 and a one year high of $26.00. The stock has a 50-day moving average price of $22.05 and a two-hundred day moving average price of $22.25.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.